Muzumdar Lab

Studying genetic, environmental, and host factors in tumor progression of #PancreaticCancer and #LungCancer @YaleGenetics @YaleCancer @CancerYale @YaleMed

[Yale West Campus @YaleWestCampus]

Congratulations to @Nelson_LaMarche, assistant professor @yalepathology @CancerYale, who has received a Breaking Barriers in Cancer Research award from the V Foundation https://t.co/Nr74RoJSxT @TheVFoundation

[Siyuan (Steven) Wang @SStevenWang]

Thank you, Yale Medicine Magazine, for highlighting my lab and my amazing colleagues Professors Etienne Caron, Liza Konnikova, Smita Krishnaswamy, and Sai Zhang in this nice article introducing the diverse and fundamental biomedical research at @YaleMed.
https://t.co/JncvWmXhmu

[Muzumdar Lab @MuzumdarLab]

Check out his @NatureComms paper: https://t.co/ACkedgdLiu

[Muzumdar Lab @MuzumdarLab]

Congrats to MD/PhD student Dan McQuaid on defending his thesis! His work established islet CCK as a bona fide driver of #obesity-driven #PancreaticCancer, positioning it as a potential risk biomarker and prevention target. @YaleMDPhD @YaleCancer @CancerYale @YaleGenetics

[Yale Cancer Center @YaleCancer]

Dr. Luisa Escobar-Hoyos @Escobar_Lab explains the challenges within #pancreaticcancer treatment, how patient outcomes can be improved, new drugs offering hope for patients, and more in this Q&A.
https://t.co/i9WDUZbIje
@SmilowCancer @YaleRadOnc

[Yale School of Medicine @YaleMed]

Pancreatic #cancer is among the deadliest cancers, with a five-year #survival rate of just 13%. In a @Yale Q&A, YSM's Luisa Escobar-Hoyos, PhD, explains what makes this "silent disease" so hard to detect – and so challenging to treat after #diagnosis: https://t.co/w0Y8k5TLAy

[Yale Department of Genetics @YaleGenetics]

It's not how much fat you eat, it's what kind 🥑

@YaleMed Prof. Mandar Muzumdar @MuzumdarLab shows how monounsaturated fats protect pancreatic cancer cells from ferroptosis, while polyunsaturated fats increase their vulnerability.
See more here👇https://t.co/iXOLQTjKJg

[Yale Cancer Center @YaleCancer]

Research from @Escobar_Lab + team identified a metabolic vulnerability in an aggressive subtype of #pancreaticcancer. Targeting the #K17-driven pathway improved chemotherapy response and doubled survival in preclinical models.
https://t.co/TnFfS2LxH1
@SmilowCancer @CR_AACR

[Yale Cancer Biology Institute @CancerYale]

Great job Gigi and all at the Muzumdar and Liu Labs! We love to see these collaborative papers among our amazing labs at #YCBI @Yanshen73854711 @MuzumdarLab @YaleWestCampus @YaleCancer @YaleMed

[Yale Cancer Biology Institute @CancerYale]

Join us for a MORNING seminar: “From mouse to man: Genetically engineered mouse models reveal conserved mechanisms of metastasis in human cancer” with Cory Abate-Shen, Columbia University, Friday June 5 @ 9:00AM, at YCBI #YCBI
@YaleCancer @YaleMed @YaleWestCampus

[Yale Cancer Center @YaleCancer]

New research from @MuzumdarLab identifies PI3K-driven wild-type RAS activation as a key mechanism of resistance to KRAS inhibition in #pancreaticcancer. Combining PI3K and KRAS inhibition may help enhance therapeutic response in PDAC.
https://t.co/kYgAleWKp9
@SmilowCancer @CR_AACR

[Muzumdar Lab @MuzumdarLab]

💡 This redefines the classic KRAS→PI3K hierarchy and reveals a bypass route that supports resistance to mutant KRAS–specific inhibitors. Special thanks to collaborators (@Yanshen73854711 @moitrayee_lab) and funders (@NIH @NSF @lustgartenfdn @AmericanCancer)!

[Muzumdar Lab @MuzumdarLab]

🎉 Excited to share our new paper led by @Xiangyu_GigiG in @CR_AACR! 🧬 We flip the script on the RAS/PI3K relationship: PI3K is more than a RAS effector, it is also its regulator! @YaleCancer @CancerYale @YaleMedicine @YaleGenetics @yalepathology
https://t.co/4i1MzYhHWh

[Muzumdar Lab @MuzumdarLab]

🧩Mechanistically, PI3K activity promotes PIP3-dependent membrane recruitment of GAB1 to form an EGFR/SHP2/SOS1 signalosome, enabling wild-type RAS/MAPK signaling. What’s more? This leads to resistance to KRAS inhibition, providing a rationale for co-targeting PI3KI and KRAS. 🎯

[Yale Cancer Center @YaleCancer]

.@YaleCancer #GrandRounds, Dr. Prasanna Ananth asks, “What defines high-quality end-of-life care for children with #cancer?” and provides insight into both what and how we measure what is most important to families with children facing #advancedcancer. #childhoodcancer. Watch her full talk https://t.co/Bn1sJAb29K
@SmilowCancer @YalePediatrics

[Yale School of Medicine @YaleMed]

In a new study, @YaleGenetics researchers report that when it comes to your risk of pancreatic #cancer, the types of #fat in your #diet matter more than the amount of fat consumed: https://t.co/ZoTZ9Ctlvh

[Yale West Campus @YaleWestCampus]

New findings from @MuzumdarLab @CancerYale suggest that, for pancreatic cancer, the type of fat you consume matters more than the amount. https://t.co/klqdhd0tkc @CD_AACR

[Elizabeth McKenna @ElizSMcKenna]

Now online in @CD_AACR: Diet-induced Phospholipid Remodeling Dictates Ferroptosis Sensitivity and Tumorigenesis in the Pancreas - by @ChristianFRuiz @MuzumdarLab and colleagues @YaleGenetics @YaleCancer @CancerYale @YaleMed

[Yale Cancer Center @YaleCancer]

New research from @MuzumdarLab shows it’s not how much fat you eat, but the type that may drive risk of #pancreaticcancer. Some fats were found to even suppress tumors.
https://t.co/KHjkndvNZb
@SmilowCancer @YaleGenetics @CD_AACR

[Christian F. Ruiz @ChristianFRuiz]

How does diet causally influence tumor development?

Fat composition—not amount—rewires the pancreatic lipidome to control ferroptosis sensitivity and tumorigenesis.

Grateful to all collaborators and excited to build on this! 👇